Biodegradable microsphere-hydrogel ocular drug delivery system

1. A method of delivering a compound to an eye, the method comprising:

applying to or into an eye of a mammal a composition in a first physicochemical state, wherein the composition comprises a treatment agent microencapsulated in degradable microcapsules suspended in a degradable thermo-responsive hydrogel, wherein the degradable microcapsules comprise polyethylene glycol (PEG), Mg(OH) 2 , bovine serum albumin, and sucrose;

wherein the composition changes to a second physicochemical state upon administration, wherein the second physicochemical state is more solid than the first physicochemical state, and wherein the degradable microcapsules release the microencapsulated treatment agent over time after applying.

2. The method of claim 1 , wherein the composition further comprises a non-encapsulated treatment agent dispersed within the degradable thermo-responsive hydrogel.

3. The method of claim 1 , wherein the microencapsulated treatment agent comprises an anti-VEGF agent, an anti-PDGF agent, cells, delivery cells, antibiotic, a corticosteroid, enzymes, peptides, nucleic acids, or combinations thereof.

4. The method of claim 3 , wherein the degradable microcapsules comprise copolymers of poly(lactic-co-glycolic acid) and chitin, polyethylene glycol, or diacrylate.

5. The method of claim 4 , wherein the microencapsulated treatment agent comprises poly(lactic-co-glycolic acid), poly(lactic acid), polysaccharide chitin, alginate, or combinations or block copolymers thereof.

6. The method of claim 1 , wherein the hydrogel comprises poly(N-isopropylacrylamide), poly(latic acid), polysaccharide chitin, alginate, diacrylate, or combinations or block copolymers thereof.

7. The method of claim 1 , wherein the second physicochemical state is degradable to release the microencapsulated treatment agent and further comprising controlling the degradation by type and/or amount of crosslinking to control the release of the microencapsulated treatment agent.

8. The method of claim 1 , wherein the composition comprises a second microencapsulated treatment agent suspended in the thermo-responsive hydrogel, the second microencapsulated treatment agent having a different rate of release than the microencapsulated treatment agent.

9. The method of claim 1 , further comprising applying the composition in a first physicochemical state by intravitreal injection, by periocular or transcleral injection, by topical application, by intracameral application, by suprachoroidal application, within ocular implants, or combinations thereof.

10. The method of claim 1 , further comprising applying the composition in a first physicochemical state by small gauge needle or microcatheter.

11. The method of claim 1 , further comprising applying the composition in a first physicochemical state as a scleral structure during retinal detachment treatment.

12. The method of claim 1 , wherein the hydrogel is thermo-responsive at a physiological temperature of about 32° C. to about 37° C.

13. The method of claim 1 , wherein the thermo-responsive hydrogels are in a liquid-like state at room temperature and more solid state at body temperature.

14. The method of claim 1 , wherein the degradable microcapsules release the microencapsulated treatment agent over 196 days after applying.

15. A method of delivering a compound to an eye, the method comprising:

applying to or into an eye of a mammal a composition in a first physicochemical state, wherein the composition comprises a treatment agent microencapsulated in degradable microcapsules that are suspended in a degradable thermo-responsive hydrogel, wherein the thermo-responsive hydrogels comprise a liquid-like state at room temperature and a more solid state at body temperature, and the suspended degradable microcapsules comprise poly(lactic-co-glycolic acid), polyethylene glycol (PEG), Mg(OH) 2 , bovine serum albumin, and sucrose;

wherein the composition changes to a second physicochemical state upon administration, wherein the second physicochemical state is more solid than the first physicochemical state, and wherein the degradable microcapsules release the microencapsulated treatment agent over six months after applying.

16. The method of claim 15 , wherein the degradable microcapsules comprise copolymers of the poly(lactic-co-glycolic acid) and chitin, polyethylene glycol, or diacrylate.

17. The method of claim 15 , wherein the second physicochemical state is degradable to release the microencapsulated treatment agent and further comprising controlling the hydrogel degradation by type and/or amount of crosslinking to control the release of the microencapsulated treatment agent.

18. The method of claim 17 , wherein the composition comprises a second microencapsulated treatment agent suspended in the thermo-responsive hydrogel, the second microencapsulated treatment agent having a different rate of release than the microencapsulated treatment agent.

19. The method of claim 17 , wherein the composition further comprises a non-encapsulated treatment agent dispersed within the degradable thermo-responsive hydrogel.

20. A method of delivering a compound to an eye, the method comprising:

applying to or into an eye of a mammal a composition in a first physicochemical state, wherein the composition includes a microencapsulated treatment agent suspended in a degradable thermo-responsive hydrogel, wherein the microencapsulated treatment agent comprises degradable microcapsules formed of poly(lactic-co-glycolic acid), polyethylene glycol (PEG), Mg(OH) 2 , bovine serum albumin, and sucrose;

wherein the composition changes to a second physicochemical state upon administration, wherein the second physicochemical state is more solid than the first physicochemical state, and wherein the degradable microcapsules release the microencapsulated treatment agent over time after applying.